FDA approves KALYDECO for treatment of eligible infants with cystic fibrosis
KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians
KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians
The collaboration will combine the genomics, chemistry and clinical data of AstraZeneca with the target identification platform and biomedical knowledge graph of BenevolentAI. BenevolentAI’s biomedical knowledge graph is
Under the collaboration, Iktos virtual drug design technology will be implemented and applied to various Janssen small molecule drug discovery programs. The French firm will collaborate with the
The CHMP’s recommendation is for the use of LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or
Luspatercept is an erythroid maturation agent (EMA), which has been designed to regulate late-stage red blood cell maturation. The drug is being jointly developed by Acceleron and Celgene
Relevance of the Study The purpose of the study is to explore using 68Ga-Tilmanocept as an aid in TB patient management while contributing to the better understanding of
In the monotherapy arm of the study, KEYTRUDA met a primary endpoint by demonstrating noninferiority to chemotherapy, the current standard of care, for overall survival (OS) in the
Smart Pharma will operate Smart-ACT, a computational repurposed drug discovery, modeling and validation platform, which uses latest technology for systematic screening of existing approved drug molecules against certain
The Israeli pharma came to the decision after a pre-specified futility analysis showed that fremanezumab was unlikely to meet the primary endpoint of a phase 3 trial in
The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available